Ocugen’s Debt Refinancing Clears a Path for Three Gene Therapy Candidates

Ocugen raises $99.5M via convertible notes, pays off high-interest loan, and advances three gene therapy programs toward FDA decisions with cash runway into 2028.

Ocugen has wiped an expensive loan off its books and locked in a fresh $115 million cash injection, giving the gene therapy developer enough runway to push three pipeline programs toward regulatory decisions. The biotech closed a convertible note placement on May 7, 2026, netting roughly $99.5 million after discounts and transaction costs, and immediately used $32.7 million of that to repay and terminate its Avenue loan—a credit line carrying a punishing 12.5 percent interest rate.

The new unsecured convertible notes, which carry a 6.75 percent coupon and mature in 2034, represent a significant cost saving. Investors can convert the debt into equity at around $2.68 per share, a 45 percent premium to the May 4 closing price. The notes also include a put option starting in 2032 and buyback rights tied to major corporate events. On a pro forma basis, Ocugen would have held roughly $99 million in cash at the end of March. If Janus Henderson exercises its outstanding warrants, an additional $15 million would boost the total cushion to about $127 million—enough, the company says, to fund operations into 2028.

With the balance sheet restructured, attention shifts squarely to the clinical calendar. The lead program, OCU400, is a gene therapy candidate for retinitis pigmentosa that targets more than 25 genetic mutations through a genagnostic mechanism. Ocugen completed enrollment of 140 patients in the Phase 3 liMeliGhT study and expects topline data in the first quarter of 2027. A rolling BLA submission is slated to begin in the third quarter of 2026, with completion targeted by the second quarter of 2027. The company is aiming for potential FDA approval in the fourth quarter of 2027.

The second program, OCU410ST for Stargardt disease, enrolled 63 patients in under nine months. Interim data are due in the third quarter of 2026, with a BLA submission planned for mid-2027. Meanwhile, OCU410, targeting geographic atrophy in dry age-related macular degeneration, delivered 12-month Phase 2 data showing a statistically significant 31 percent reduction in lesion growth versus the control group—a result Ocugen describes as double the efficacy of approved therapies. A Phase 3 study for OCU410 is expected to begin in the third quarter of 2026, with a BLA filing penciled in for 2028.

The operational progress comes at a cost. First-quarter 2026 operating expenses rose to $19.4 million from $16.0 million a year earlier, with research and development accounting for $11.3 million. The net loss per share stood at $0.06.

The stock, however, has not shared the optimism. Trading at roughly $1.24, the shares have fallen more than 20 percent over the past 30 days and sit about 43 percent below their 52-week high from March. The relative strength index of 36 points to oversold territory. On a 12-month basis, the stock remains up over 100 percent, but the near-term selling pressure reflects investor skepticism about whether the ambitious regulatory timeline will hold.

The next major catalysts arrive in the third quarter of 2026, when Ocugen releases interim data for OCU410ST and simultaneously kicks off the rolling BLA process for OCU400. Those two events will test whether the refinancing and pipeline progress can finally shift market sentiment.